Link in Most Popular box

Funded Boostrix® in pregnancy

Wednesday, 12 December 2012

PHARMAC have extended the availability of funded Boostrix® for pregnant women between 28-38 weeks gestation from 1 January 2013.

New Zealand is in the midst of a pertussis epidemic. PHARMAC recently sought feedback on a proposal to extend funded Boostrix® for pregnant women in addition to those aged 11 years as per the National Immunisation Schedule.

Considerations and commentary around this decision are available in the PHARMAC media release.

2013 National Immunisation Workshop and Conference

Start: 10/09/2013 09:00

End: 12/09/2013 16:00

The conference will present recent research from areas of disease control, global approaches to immunisation, post marketing surveillance, immunisation communication using social media, adult vaccination and specialised programmes and future vaccines.

The Workshop and Conference is being held on 10-12 September at the Waipuna Hotel & Conference Centre.

Dr Marc LaForce, founding director of the Meningitis Vaccine Project is our keynote speaker. Dr LaForce led the successful development, licensure, and introduction of MenAfriVac™, the first vaccine designed specifically for Africa, and directed the project from 2001 until his retirement in 2012. The remainder of the programme is being finalised, to date there are five plenary sessions with breakout sessions allowing additional presentations and discussions around these themes:

Immunisation research
Effective use of vaccines
Immunisation quality systems
Immunisation coverage/vaccine preventable disease management

Attracting local, national and international speakers and attendees the conference will also provide an excellent opportunity to network. More information about the conference and pre-conference workshop programme and speakers will be posted on our conference website as they become available.

The closing date for the Call for Abstracts is 8pm on Wednesday 5 June 2013 with no exceptions.

Calendar

Meningococcal vaccines in detail

Link to vaccine data sheet	Vaccine type	Indications and dose	Booster dose If still at risk
Menactra®	Meningococcal A,C,Y,W-135 conjugate	9-23 months^{(off-label* based on FDA product approval)} Two doses separated by three months 24 months to 55 years^{(NZ licensure)} One dose From 56 years^{(off-label* use)} One dose	9-23 months^{(off-label* based on FDA product approval)} Three years later, then Every five years 24 months to 55 years^{(NZ licensure)} Every five years From 56 years^{(off-label* use)} Every five years _{Menactra® MUST be administered a minimum of four weeks after Prevenar 13® to ensure the best immune response to the pneumococcal vaccine.}
^{*Section 25 of the Medicines Act 1981 allows off-label use of medicines (including vaccines) providing that doctors have informed consent from the patient and exercise a duty of care.}
Meningitec®	Meningococcal C conjugate	6 weeks to 11 months Three doses, each dose separated by four weeks One dose at 12 months of age, a minimum of eight weeks after dose three From 12 months One dose	12 months to 6 years Three years later, then Every five years from 6 years of age If ≥ 6 years Every 5 years
NeisVac-C™	Meningococcal C conjugate	8 weeks to 11 months Two doses separated by eight weeks One dose at 12 months of age, a minimum of eight weeks after dose two From 12 months One dose	12 months to 6 years Three years later, then Every five years from 6 years of age If ≥ 6 years of age Every 5 years
Menomune® ACYW-135	Meningococcal A,C,Y,W-135 polysaccharide	From 2 years One dose	If ≤ 5 years at time of first dose Revaccinate once after 2-3 years If ≥ 6 years at time of first dose Revaccinate once after 3-5 years
Mencevax® ACWY	Meningococcal A,C,Y,W-135 polysaccharide	From 2 years One dose	If ≤ 5 years at time of first dose Revaccinate once after 2-3 years If ≥ 6 years at time of first dose Revaccinate once after 3-5 years

Healthcare Logistics order form - 21 January 2013

Boostrix®

Tdap

Boostrix® is used for booster vaccination of adolescents aged 11 years and pregnant women between 28-38 weeks gestation to protect against diphtheria, tetanus and pertussis (whooping cough).
*After immunisation protection against pertussis takes up to two weeks to develop. Whilst immunisation between 38-40 weeks gestation is still safe for mother and baby later immunisation means the newborn may still be exposed to the disease by their mother on delivery and/or during the first two weeks of life. The PHARMAC decision to limit funded Boostrix® to 28-38 weeks gestation maximises the benefit of immunisation against pertussis whilst being accountable for the use of public funds. Pregnant women can choose to purchase Boostrix® privately after 38 weeks gestation or at any time after delivery.
Boostrix® is licensed for use in children 10 years of age and over and adults as a booster vaccine. Boostrix® can be used, out of licensure in children from 7 years of age and adults, for one or all three doses of a primary course of tetanus and diphtheria vaccination, so as to provide protection from pertussis (whooping cough). There is no alternative vaccine that provides protection from pertussis available in New Zealand for this age group.
When children are younger than the age to which the vaccine is licensed, and when the vaccine is used for a primary vaccination course, use will be outside of current licensure and parents/guardians/individuals must be fully informed of this. There are not expected to be any safety concerns for use in these circumstances.

Link in Most Popular box

Funded Boostrix® in pregnancy

2013 National Immunisation Workshop and Conference

Meningococcal vaccines in detail

_{Menactra® MUST be administered a minimum of four weeks after Prevenar 13® to ensure the best immune response to the pneumococcal vaccine.}

Boostrix®

Most Popular

Newsletter

Tag Cloud

Pages

Support

Site

Terms